ArticlePloS one2025
Gardenia jasminoides fruit extract ameliorates non-alcoholic steatohepatitis with fibrosis by modulating inflammatory and fibrogenic pathways.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dietary Isorhamnetin Alleviates Alcoholic Liver Injury in Mice by Regulating Gut Microbiota via the Gut-Liver Axis.Nutrients · 2026Article
- Review
- Total Flavonoids ofNutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in drug development, treatment for non-alcoholic steatohepatitis (NASH)-related liver fibrosis remains limited, underscoring the need for more effective therapeutic strategies. Gardenia jasminoides exhibits promising anti-inflammatory and anti-fibrotic properties, suggesting its potential as a therapeutic candidate for NASH-related liver fibrosis. Accordingly, this study aimed to investigate the therapeutic potential of Gardenia jasminoides fruit extract (GJE) in a rat model of NASH with fibrosis induced by a high-fat, high-fructose (HFHF) diet, and to elucidate the underlying molecular mechanisms. Male Sprague-Dawley rats were randomly assigned to four groups (n = 6/group): 1) Control group, fed a standard diet; 2) NASH with fibrosis group (NF), fed a HFHF diet for 20 weeks; 3) Low-dose GJE group (NF + Low dose GJE), treated with 0.119 g/kg BW of GJE; and 4) High-dose GJE group (NF+High dose GJE), treated with 0.239 g/kg BW of GJE. GJE was administered via intragastric gavage once daily from weeks 13-20. Serum markers of liver injury (ALT and AST) were assessed. Liver histology was examined to evaluate NASH and fibrosis severity. Immunohistochemistry was performed to detect NF-kB p65 and Col1a1 expression and protein levels of MMP-12, α-SMA, IL-13 and TGF-β1 were quantified. Serum ALT and AST levels were significantly increased in the NF group, which also showed the highest NASH histopathology scores and collagen deposition. GJE treatment significantly reduced ALT and AST levels in both low- and high- dose groups. The low-dose GJE group showed marked improvement in NASH histopathology, while both treatment groups exhibited reduced hepatic collagen deposition. GJE treatment significantly suppressed NF-kB p65 and Col1a1 expression, along with downregulation of MMP-12, α-SMA, IL-13 and TGF-β1 protein levels. In conclusion, GJE effectively ameliorated HFHF diet-induced NASH with fibrosis by modulating inflammatory and fibrogenic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.